Henan Taloph Pharmaceutical Stock Co Ltd (600222) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Henan Taloph Pharmaceutical Stock Co Ltd (600222) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥22.69 Million ≈ $3.32 Million USD) by net assets (CN¥1.65 Billion ≈ $241.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Henan Taloph Pharmaceutical Stock Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2024)
This chart illustrates how Henan Taloph Pharmaceutical Stock Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 600222 total debt and obligations for a breakdown of total debt and financial obligations.
Henan Taloph Pharmaceutical Stock Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Henan Taloph Pharmaceutical Stock Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zoje Resources Investment Co Ltd
SHE:002021
|
0.007x |
|
Taekwang Ind
KO:003240
|
-0.011x |
|
Southern Cable Group Bhd
KLSE:0225
|
0.036x |
|
Sijin Intelligent Forming Machinery
SHE:003025
|
0.060x |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
0.048x |
|
Atlanta Braves Holdings, Inc. Series A Common Stock
NASDAQ:BATRA
|
-0.155x |
|
Bouvet
OL:BOUV
|
0.857x |
|
Ibotta, Inc.
NYSE:IBTA
|
0.066x |
Annual Cash Flow Conversion Efficiency for Henan Taloph Pharmaceutical Stock Co Ltd (1998–2024)
The table below shows the annual cash flow conversion efficiency of Henan Taloph Pharmaceutical Stock Co Ltd from 1998 to 2024. For the full company profile with market capitalisation and key ratios, see Henan Taloph Pharmaceutical Stock Co Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.63 Billion ≈ $237.97 Million |
CN¥-39.59 Million ≈ $-5.79 Million |
-0.024x | -190.35% |
| 2023-12-31 | CN¥1.62 Billion ≈ $237.55 Million |
CN¥43.74 Million ≈ $6.40 Million |
0.027x | +134.96% |
| 2022-12-31 | CN¥1.61 Billion ≈ $236.19 Million |
CN¥-124.41 Million ≈ $-18.20 Million |
-0.077x | -237.49% |
| 2021-12-31 | CN¥1.78 Billion ≈ $260.12 Million |
CN¥99.66 Million ≈ $14.58 Million |
0.056x | +16.86% |
| 2020-12-31 | CN¥1.53 Billion ≈ $223.97 Million |
CN¥73.43 Million ≈ $10.74 Million |
0.048x | +51.55% |
| 2019-12-31 | CN¥1.31 Billion ≈ $191.96 Million |
CN¥41.53 Million ≈ $6.08 Million |
0.032x | -63.14% |
| 2018-12-31 | CN¥1.39 Billion ≈ $203.58 Million |
CN¥119.47 Million ≈ $17.48 Million |
0.086x | +459.02% |
| 2017-12-31 | CN¥1.51 Billion ≈ $220.70 Million |
CN¥23.17 Million ≈ $3.39 Million |
0.015x | -67.36% |
| 2016-12-31 | CN¥1.50 Billion ≈ $219.49 Million |
CN¥70.60 Million ≈ $10.33 Million |
0.047x | +43.24% |
| 2015-12-31 | CN¥1.50 Billion ≈ $219.41 Million |
CN¥49.27 Million ≈ $7.21 Million |
0.033x | -56.47% |
| 2014-12-31 | CN¥1.19 Billion ≈ $173.57 Million |
CN¥89.54 Million ≈ $13.10 Million |
0.075x | +1340.44% |
| 2013-12-31 | CN¥1.09 Billion ≈ $159.85 Million |
CN¥-6.65 Million ≈ $-972.81K |
-0.006x | -104.57% |
| 2012-12-31 | CN¥656.50 Million ≈ $96.07 Million |
CN¥87.45 Million ≈ $12.80 Million |
0.133x | +79526.32% |
| 2011-12-31 | CN¥628.89 Million ≈ $92.03 Million |
CN¥105.20K ≈ $15.39K |
0.000x | +100.51% |
| 2010-12-31 | CN¥609.32 Million ≈ $89.16 Million |
CN¥-20.00 Million ≈ $-2.93 Million |
-0.033x | -189.72% |
| 2009-12-31 | CN¥586.04 Million ≈ $85.76 Million |
CN¥21.45 Million ≈ $3.14 Million |
0.037x | +12.00% |
| 2008-12-31 | CN¥554.97 Million ≈ $81.21 Million |
CN¥18.13 Million ≈ $2.65 Million |
0.033x | -20.12% |
| 2007-12-31 | CN¥521.57 Million ≈ $76.32 Million |
CN¥21.34 Million ≈ $3.12 Million |
0.041x | +1149.87% |
| 2006-12-31 | CN¥487.05 Million ≈ $71.27 Million |
CN¥1.59 Million ≈ $233.25K |
0.003x | +459.04% |
| 2005-12-31 | CN¥471.96 Million ≈ $69.06 Million |
CN¥276.30K ≈ $40.43K |
0.001x | -98.54% |
| 2004-12-31 | CN¥455.68 Million ≈ $66.68 Million |
CN¥18.25 Million ≈ $2.67 Million |
0.040x | +371.94% |
| 2003-12-31 | CN¥440.61 Million ≈ $64.48 Million |
CN¥3.74 Million ≈ $547.22K |
0.008x | -51.32% |
| 2002-12-31 | CN¥428.30 Million ≈ $62.67 Million |
CN¥7.47 Million ≈ $1.09 Million |
0.017x | -86.79% |
| 2001-12-31 | CN¥416.84 Million ≈ $61.00 Million |
CN¥55.03 Million ≈ $8.05 Million |
0.132x | +6089.51% |
| 2000-12-31 | CN¥410.41 Million ≈ $60.06 Million |
CN¥875.36K ≈ $128.09K |
0.002x | -99.14% |
| 1999-12-31 | CN¥401.57 Million ≈ $58.76 Million |
CN¥99.32 Million ≈ $14.53 Million |
0.247x | +36.58% |
| 1998-12-31 | CN¥154.84 Million ≈ $22.66 Million |
CN¥28.04 Million ≈ $4.10 Million |
0.181x | -- |
About Henan Taloph Pharmaceutical Stock Co Ltd
Henan Taloph Pharmaceutical Stock Co.,Ltd engages in the research, development, and sale of pharmaceutical preparations and Chinese herbal medicines in China. Its principal products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, pediatric Qingrezhike oral liquid, Huoxiangzhengqi mixture, Danshen and Wuzi Yanzong oral liquid, Shengmaiyin, pediatric compound chicken gizzard chew… Read more